

1 **Pluripotent Stem Cells Can Be Isolated from Human Peripheral Nerves after *in***
2 ***vitro* BMP-2 Stimulation**

3 Ren-Yi Sun^{1,3}, Michael H. Heggeness², Tanghong Jia¹, Sunaina Shrestha³, Bradley Dart², Shang-
4 You Yang^{2,3*}

5 ¹Jinan Central Hospital, Shandong University, Jinan, Shandong, China

6 ²Department of Orthopaedic Surgery, University of Kansas School of Medicine – Wichita,
7 Wichita, Kansas, United States of America

8 ³Department of Biological Sciences, Wichita State University, Wichita, Kansas, United States of
9 America

10

11 *Corresponding Author

12 E-mail: syang6@kumc.edu

13 Abstract

14 We have recently identified a population of cells within the peripheral nerves of adult mice that
15 can respond to BMP-2 exposure or physical injury to rapidly proliferate. More importantly, these
16 cells exhibited embryonic differentiation potentials that could be induced into osteoblastic and
17 endothelial cells in vitro. The current study examined human nerve specimens to compare and
18 characterize the cells after BMP-2 stimulation. Fresh pieces of human nerve tissue were minced
19 and treated with either BMP-2 (750ng/ml) or vehicle for 12 hours at 37°C, before digested in
20 0.2% collagenase and 0.05% trypsin-EDTA. Isolated cells were cultured in restrictive stem cell
21 medium. Significantly more cells were obtained from the nerve pieces with BMP-2 treatment in
22 comparison with the non-treated controls. Cell colonies were starting to form at day 3.
23 Expressions of the 4 transcription factors Klf4, c-Myc, Sox2 and Oct4 were confirmed at both
24 transcriptional and translational levels. The cells can be maintained in the stem cell culture
25 medium for at least 6 weeks without changing morphologies. When the cells were switched to
26 fibroblast growth medium, dispersed spindle-shaped cells were noted and became fibroblast
27 activated protein- α (FAP) positive following immunocytochemistry staining. The data suggested
28 that human peripheral nerve tissue also contain a population of cells that can respond to BMP-2
29 and express all four transcription factors KLF4, Sox2, cMyc, and Oct4. These cells are capable to
30 differentiate into FAP-positive fibroblasts. It is proposed that these cells are possibly at the core
31 of a previously unknown natural mechanism for healing injury.

32

33 Key words: Mouse; human; Peripheral nerve; Pluripotent stem cells; rhBMP-2; fibroblasts

34

35 Introduction

36 The potential for stem cells to treat human disease is rightly perceived to be vast. Embryonic
37 stem cells (ESCs) from inner cell mass of mammalian blastocyst that have unlimited self-renewal
38 and pluripotency are capable of differentiate into ectodermal, mesodermal, and endodermal
39 cells [1, 2]. Based on the stud of previous, the ESCs behave undifferentiated morphology [3].
40 Although there are numerous ongoing studies to investigate the therapeutic potentials of human
41 embryonic stem cells (hESCs) for type I diabetes (T1D), heart failure, Parkinson’s disease and
42 inherited or acquired retinal degenerations [4], challenges remain to be conquered in clinical
43 development of hESCs such as legal and ethical issues, immune rejections, and differentiation
44 difficulties [3]. Somatic cells can be introduced to transform into a state of pluripotency [3]. The
45 brilliant work of Drs. Yamanaka and Takayashi [5, 6] demonstrated that pluripotent cells can be
46 created from adult differentiated cells by the virally induced manipulation of nuclear genes to
47 force expression of 4 specific transcription factors, octamer-binding transcription factor 4 (OCT4),
48 sex determining region Y-box 2 (SOX2), Krüppel-like family of transcription factor 4 (KLF4) and c-
49 Myc that will convert the cells to pluripotency. Unfortunately, this process creates a very real
50 risk of malignant transformation, and does not solve the issue of immune rejection, as the cells
51 are “non-self”. Another drawback is that such cells are expensive to create and assessing the cells
52 for risk of malignant transformation adds further time and expense. At best it can diminish this
53 risk, but does not eliminate it [7, 8]. We have serendipitously discovered a population of
54 pluripotent cells that reside in a quiescent state within mouse peripheral nerves [9, 10]. When
55 the nerves are stimulated with physical insult (including mechanical compression or stretching,

56 exposure to blood, and electrical or cytokine BMP2 stimulation) a massive proliferation of cells
57 within the nerve results with a rapid egress of the cells into the surrounding tissues. These
58 proliferating cells uniformly exhibit expression of the 4 critical genes associated with pluripotency;
59 Sox2, Oct4, c-Myc, and Klf4 as demonstrated by double stain immunohistochemistry and by Real
60 Time Polymerase Chain Reaction (RT-PCR) with appropriate primers [10]. They are readily
61 cultured in restrictive media, adhere to substrate, and appear motile. They have been
62 successfully differentiated into cells of the three primary germ layers: mesoderm (osteoblasts
63 and endothelial cells) [9], endoderm (Definitive Endoderm), and ectoderm (Primitive Nerve Cells)
64 in rodents (unpublished data). We have termed these cells Nerve Derived Adult Pluripotent Stem
65 cells, or NEDAPS cells.

66 Indeed, there are too many instances that the biological data from rodent experiments did not
67 conform to human tissue responses. The objective of this study was to examine the
68 characteristics and differentiation potential of these pluripotent stem cells, remarkably,
69 obtainable from adult human peripheral nerves.

70

71 Materials and Methods:

72 Human peripheral nerve tissue treatment

73 This study was exempted by the institutional Review Board (IRB) as a non-human investigation.

74 Fresh human peripheral nerves were obtained as surgical waste in a completely anonymous

75 fashion from 3 serious trauma patients during limb amputation. This was tissue that would

76 normally have been discarded. No identifying features of the specimens was shared or recorded.
77 The peripheral nerve tissues were stored in sterile normal saline on ice and transferred to the
78 research lab within one hour from the amputated limb. The nerves were immediately minced
79 and put into a 6-well culture plates (CytoOne, USA Scientific, Ocala, FL, USA) with DMEM medium
80 and 275 ng/ml of rhBMP-2 (InFuse™, Medtronic, Memphis, TN) was added to each well. The
81 minced nerve tissue was incubated overnight at 37 °C before cell isolation.

82

83 Mouse sciatic nerve treatment

84 Thirty (30) BALB/c mice at age of 10 weeks were used for this study. The institutional Animal Care
85 and Use Committee (IACUC) approved all the animal protocols, and the surgical procedures were
86 performed as reported previously {Heggeness, 2017 #50} . Briefly, both hind legs of mouse were
87 shaved and disinfected after anesthesia by intraperitoneal injection of 8mg/kg Xylazine and
88 90mg/kg Katamin. Under strict sterile condition, sciatic nerve was surgically exposed through
89 lateral incision, and 20 µl of rhBMP-2 applied to the nerve. The wound was closed in layers, and
90 the animals were kept for 20 hours before sacrifice for the sciatic nerves harvest.

91

92 Cell isolation and Culture

93 Proliferating NEDAPS cells were isolated the same as reported previously for mouse NEDAPS cells
94 [10]. Briefly, the minced nerve pieces were pelleted by centrifugation at 500xg for 5 minutes and

95 followed by digestion in 0.2% (0.27 U/ml) collagenase (Worthington Biochemical Corp) at 37°C
96 for 90 minutes. Equal volume of 0.05% trypsin-EDTA solution was then added for 5 minutes with
97 agitation. The enzyme digestion was stopped by addition of heat-deactivated fetal bovine serum
98 (FBS) and the mixture was filtered through a 100µm-sized mesh before centrifugation at 500xg
99 for 10 min to pellet cells. The cells were seeded into 6-well culture dishes, or 8-well chamber-
100 slides in the restriction stem cell medium with 20% Knockout serum replacement (KSR, Gibco),
101 100µM MEM non-essential amino-acid solution (Gibco), 1x GlutaMAX™-I (Gibco); 55µM β-
102 mercaptoethanol (Gibco), and 20 ng/ml human leukemia inhibitory factor (LIF, Gibco). The cells
103 were cultured at 37°C, 5%CO₂ atmosphere. For fibroblast induction, the human NEDAPS cells
104 were switched to the fibroblast induction medium that contains 20 ng/mL recombinant human
105 FGF-2 (rhFGF-2), 50 µg/mL Ascorbic Acid, and 10% FBS in DMEM.

106

107 Real-time PCR (RT-PCR) test

108 For RNA isolation, the cells were resuspended and lysed in TRIzol solution (Life Technologies,
109 Carlsbad, CA, USA), and then went through chloroform separation and isopropanol precipitation
110 following the protocol described by Chomczynski [11, 12]. Complementary DNA (cDNA) was
111 made by reverse transcription in the 40 µl mixture as follows: 4 µl 10 × PCR Rxn buffer (-MgCl₂)
112 (Invitrogen, Grand Island, NY, USA), 4.4 µl MgCl₂ in the concentration of 5.5mM (Invitrogen), 8 µl
113 deoxynucleoside triphosphates in the concentration of 500 µM (Invitrogen), 2 µl RNase inhibitor
114 in the concentration of 0.5 U/µl (Invitrogen), 2 µl random hexamers in the concentration of 2.5
115 µM (Invitrogen), 0.25 µl reverse transcriptase in the concentration of 1.25 U/µl (Invitrogen), 9.35

116 μ l DNase, RNase free water (Invitrogen) and 0.5 μ g of extracted RNA. The reactions were in fast
117 reaction tubes on a Veriti 96-well Thermal Cycler (Applied Biosystems, Foster City, CA, USA). The
118 temperature cycle was: at 25°C for 10 minutes, 48 °C for 30 minutes and 95 °C for 5 minutes. RT-
119 PCR was run on a StepOnePlus RT-PCR System (Applied Biosystems) for forty cycles in fast optical
120 96-well reaction plate. The 25 μ l reaction mixture was mixed by 12.5 μ l SYBR Green PCR Master
121 Mix (Applied Biosystems), 6 μ l cDNA, 5.5 μ l DNase, RNase free water (Invitrogen) and 400 nM
122 tested gene primer pairs. The RT-PCR System can automatically record all the fluorescent signals
123 dynamically. We employed Primer3 program (<http://bioinfo.ut.ee/primer3/>) to design the
124 primer pairs for each target gene[13, 14] and made by Sigma-Genosys (Woodlands, TX, USA). The
125 gene sequences are described as in Table 1.

126

127 Immunocytochemistry staining and image acquisition

128 The immunocytochemistry staining technique for the four stem cell markers (c-Myc, Sox2, KLF4,
129 Oct4) has been reported previously [9, 10]. The following primary antibodies were used as pairs
130 for double staining: goat anti-Sox2 (Santa Cruz), goat anti-KLF4 (R&D), rabbit anti-c-Myc (Abcam),
131 goat and rabbit anti-Oct4 (Abcam), rabbit anti-Myelin (Abcam). Cells were double stained with
132 goat and rabbit first antibody pairs (Sox2 + c-Myc, KLF4 + c-Myc, Sox2 + Oct4, KLF4 + Oct4, KLF4
133 + Myelin, Oct4 + Myelin). For fibroblast differentiation, rabbit anti-FGF-2 (basic fibroblast growth
134 factor, Abcam) and rabbit anti-mouse FAB (fibroblast activation protein, Abcam) were used.
135 Following washes, the diluted secondary antibody (1:200) in 1 \times PBS with 1% BSA was added onto
136 the cells for 1h at room temperature in the dark. The secondary antibodies we utilized were

137 donkey anti-rabbit IgG conjugated with Alexa Fluor 594 (Life Technologies) and donkey anti-goat
138 IgG with Alexa 488. DAPI Fluoromount G (Southern Biotech, Birmingham, AL, USA) was used to
139 mount coverslip and to counterstain cell nuclei. Fluorescent images of the cells were acquired
140 under a Nikon E800 fluorescence microscope (Nikon, Japan), by a Coolsnap EZ CCD Camera
141 (Photometrics, Tucson, AZ, USA) and analyzed using a MetaMorph image analysis software
142 (Molecular Devices, San Francisco, CA, USA). Various stained images were overlaid by the image
143 analysis software to illustrate the co-localization patterns.

144

145 Statistical analysis

146 The data of comparative gene expression of the 4 stem cell transcription factors and the
147 fibroblast markers between groups and immunocytochemical positive cells were all recorded,
148 and expressed as mean \pm standard deviation. The data among the groups were analyzed by one-
149 way analysis of variance (ANOVA) followed by Bonferroni post-hoc test (equal variances
150 assumed). Statistical probability of $P < 0.05$ was considered as statistical significance. The
151 software for statistical analysis was IBM SPSS Statistics (Armonk, NY, USA).

152

153 Results

154

155 Morphology of the human NEDAPS cells

156 Similar to the mouse NEDAPS cells, the human cells readily adhered to the culture plates or
157 chamber-slides and maintained a polygon-shaped morphology (Figure 1A). They also did not
158 require feeder cells to survive. However, in contrast to the rodent cells [10] which were remaining
159 dispersed on the culture plate, the human cells tended to gather to form colonies. It appears that
160 the motile cells formed clusters within 24 to 48 hours in the stem cell medium, and stayed in
161 colonies during proliferation. Indeed, the cells in colonies continued to divide and could reach
162 several cell layers (Figure 1B).

163

164 Expression of stem cell markers

165 Immunofluorescent microscopy clearly showed that over 90% of the isolated human nerve cells
166 were simultaneously expressing the four transcription factors Sox2, Oct4, c-Myc and Klf4 after 5
167 days in culture in the restrictive stem cell medium. It is also noticeable that the double staining
168 illustrates the co-expressions of the stem cell markers in various pairs (Figure 2).

169 Real time PCR was performed to examine the mRNA expressions of Sox2, Oct4, c-Myc, and Klf4
170 of these cells. It is convincing that strong expressions of all the 4 transcription factors in the
171 human nerve specimens treated with BMP-2, significantly more than those obtained from non-
172 BMP2 treated nerve specimens ($p < 0.05$). Some of the samples following real-time PCR were
173 electrophoresed on an agarose gel to reveal the correct-sized PCR product of the transcription
174 factors (Figure 3).

175

176 Differentiation to fibroblasts

177 When the human NEDAPS cells were changed to the complete fibroblast induction medium, they
178 rapidly dispersed from their small colonies and assumed the classic “spindle shape” of motile
179 fibroblasts within 24 – 48 hours (Figure 4). Immunohistochemical staining against fibroblast
180 activation protein (FAP) confirmed that they become FAP-positive.

181

182 Discussion

183

184 Bone morphogenetic proteins (BMPs), first described by Marshall Urist in 1965 [15], are able to
185 stimulate the stem cell to differentiate into osteoblast cell, and are considered to be the most
186 important growth factors in bone formation and fracture healing. As members of the TGF- β
187 superfamily, the details of their status as intercellular signal transduction are still under study.
188 Among the more than 20 different human BMPs identified until now, only the BMP-2 and BMP-
189 7 are approved by the Food and Drug Administration (FDA) for clinical use. In recent years, more
190 and more Orthopedics surgeons are likely to apply BMP-2 to a variety of different clinical
191 applications for its osteoinductive function [16]. With the increase in clinical use of BMP-2, many
192 associated adverse events have been reported, most of them related to the use of BMP2 (Infuse)
193 in proximity to nerves [17]. We speculate that the use of BMP2 in proximity to nerves at vastly
194 supraphysiologic levels will likely lead to nerve dysfunction as the supraphysiologic production of
195 stem cells will result in a likelihood of permanent nerve dysfunction [10].

196 In the effort of using mouse model to investigate potential complications of BMP-2 to peripheral
197 nerves during bone healing applications, an intriguing finding was noticed that a population of
198 cells was proliferated within the nerve. Indeed, these cells were able to express the 4
199 transcription factors c-Myc, Klf4, Sox-2, and Oct-4 [10], suggesting their pluripotent potentials.
200 Further investigation also confirmed that physical injury to peripheral nerves such as
201 compression also induced the same phenomena of cell proliferations [10]. In the current study,
202 it is very interesting to note that the same population of cells can be isolated from human
203 peripheral nerve tissue after in vitro incubation with small amount of BMP-2, although the cell
204 growth pattern of human nerve induced cells appear different compare to the mouse NEDAPS
205 cells, the human tibial induced cells all huddled together and grew concentric but the mouse
206 NEDAPS cells were all dispersive.

207 The immunocytochemistry and RT-PCR both verified new gene expression (Sox2, KLF4, c-Myc,
208 Oct4), and these four transcription factors were regarded as exclusive for pluripotent stem cells.
209 Observed utilizing fluorescence microscope, the slides which were treated by immunochemical
210 technology clearly displayed the four stem cells' exclusive marker. Real-time RT-PCR technique
211 conveniently confirmed expressions of the four target genes (Sox2, KLF4, c-Myc, Oct4) and the
212 agarose electrophoresis revealed this result.

213 To illustrate the differentiation potential of the human NEDAPS cells, we switched the cell culture
214 medium to fibroblast growth medium containing recombinant human fibroblast growth factor-2
215 (rhFGF-2). The cell morphology was quickly changed with 2-3 days, and IHC staining confirmed
216 expression of fibroblast activation protein (FAP- α). FAP- α has been identified as a fibroblast

217 marker that is over-expressed in activated fibroblasts or mesenchymal stromal cells [18], the
218 differentiation ability of the human nerve-derived NEDAPS cells will be further investigated to
219 explore the clinical significance.

220 The stem cells, which are also immature cells with self-renewal capacity, are able to differentiate
221 into many kinds of somatic cells depending where they come from [19]. However, if so used as
222 an allograft cell-based therapy, the recipients would need to be under an immune-suppressive
223 therapy in order to prevent immune rejection [7, 8].

224 We are excited to report on this very recently discovered source of pluripotent cells which would
225 seem to have an exciting potential for human cell-based therapies. These cells are notably
226 different from embryonic stem cells or the induced pluripotent stem cells (iPCs), with remarkably
227 distinct appearance and behaviors compared to previously described “true embryonic stem cells”.
228 Importantly, these peripheral nerve-derived cells seem to have the natural function of
229 accomplishing tissue repair and their “niche” within peripheral nerves provides a welcome insight
230 into the pathophysiology of the wound healing problems associated with peripheral
231 neuropathies including leprosy, Diabetes mellitus and tertiary syphilis. We speculate that the loss
232 of healthy nerves in these patients means that the NEDAPS cells are no longer available to heal
233 such wounds. This insight may open the door to all manner of cell-based treatments using self-
234 to-self autografts of pluripotent NEDAPS cells or differentiated cells therefrom. This could
235 potentially allow the harvest of a non-essential peripheral nerve such as a branch of the purely
236 sensory sural nerve, of the anterior intraosseous nerve (or many others) to perhaps have a very
237 wide application for tissue regenerations.

238 In conclusion, we suggested in this study that the human peripheral nerves also contain normally
239 quiescent NEDAPS cells. Current investigation is focused on further documenting their
240 differentiation potentials and to exploring their therapeutic potential in bone and other tissue
241 repair and regeneration models. We suggest that these cells are possibly at the core of a
242 previously unknown natural mechanism for healing injury.

243

244 Acknowledgments

245 The authors wish to acknowledge valuable technical assistance of Ms. Zheng Song in the early
246 stage of the investigation.

247

248 References

- 249 1. Evans MJ, Kaufman MH. Establishment in culture of pluripotential cells from mouse
250 embryos. *Nature*. 1981;292(5819):154-6. PubMed PMID: 7242681.
- 251 2. Martin GR. Isolation of a pluripotent cell line from early mouse embryos cultured in
252 medium conditioned by teratocarcinoma stem cells. *Proc Natl Acad Sci U S A*. 1981;78(12):7634-8.
253 PubMed PMID: 6950406; PubMed Central PMCID: PMC349323.
- 254 3. Ratajczak MZ, Marycz K, Poniewierska-Baran A, Fiedorowicz K, Zbucka-Kretowska M,
255 Moniuszko M. Very small embryonic-like stem cells as a novel developmental concept and the
256 hierarchy of the stem cell compartment. *Advances in Medical Sciences*. 2014;59(2):273-80. doi:
257 10.1016/j.advms.2014.08.001.
- 258 4. Lamba DA, McUsic A, Hirata RK, Wang PR, Russell D, Reh TA. Generation, purification and
259 transplantation of photoreceptors derived from human induced pluripotent stem cells. *PLoS One*.
260 2010;5(1):e8763. doi: 10.1371/journal.pone.0008763. PubMed PMID: 20098701; PubMed
261 Central PMCID: PMC2808350.

- 262 5. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and
263 adult fibroblast cultures by defined factors. *Cell*. 2006;126(4):663-76. Epub 2006/08/15. doi:
264 10.1016/j.cell.2006.07.024. PubMed PMID: 16904174.
- 265 6. Takahashi K, Narita M, Yokura M, Ichisaka T, Yamanaka S. Human induced pluripotent
266 stem cells on autologous feeders. *PLoS One*. 2009;4(12):e8067. Epub 2009/12/04. doi:
267 10.1371/journal.pone.0008067. PubMed PMID: 19956543; PubMed Central PMCID:
268 PMCPMC2780725.
- 269 7. Fu X, Xu Y. Challenges to the clinical application of pluripotent stem cells: towards
270 genomic and functional stability. *Genome Med*. 2012;4(6):55. Epub 2012/06/30. doi:
271 10.1186/gm354. PubMed PMID: 22741526; PubMed Central PMCID: PMCPMC3698533.
- 272 8. Serra M, Brito C, Correia C, Alves PM. Process engineering of human pluripotent stem cells
273 for clinical application. *Trends Biotechnol*. 2012;30(6):350-9. Epub 2012/05/01. doi:
274 10.1016/j.tibtech.2012.03.003. PubMed PMID: 22541338.
- 275 9. Yang SY, Strong N, Gong X, Heggeness MH. Differentiation of nerve-derived adult
276 pluripotent stem cells into osteoblastic and endothelial cells. *Spine J*. 2017;17(2):277-81. Epub
277 2016/10/30. doi: 10.1016/j.spinee.2016.10.002. PubMed PMID: 27737805.
- 278 10. Heggeness MH, Strong N, Wooley PH, Yang SY. Quiescent pluripotent stem cells reside
279 within murine peripheral nerves that can be stimulated to proliferate by recombinant human
280 bone morphogenic protein 2 or by nerve trauma. *Spine J*. 2017;17(2):252-9. Epub 2016/09/25.
281 doi: 10.1016/j.spinee.2016.09.016. PubMed PMID: 27664339.
- 282 11. Chomczynski PS, N. Single step method of RNA isolation by Acid Guanidinium
283 Thiocyanate-Phenol-Chloroform Extraction. *ANALYTICAL BIOCHEMISTRY*. 1987;162:156-9.
- 284 12. Chomczynski P, Sacchi N. The single-step method of RNA isolation by acid guanidinium
285 thiocyanate-phenol-chloroform extraction: twenty-something years on. *Nature Protocols*.
286 2006;1(2):581-5. doi: 10.1038/nprot.2006.83. PubMed PMID: 17406285.
- 287 13. Koressaar T, Remm M. Enhancements and modifications of primer design program
288 Primer3. *Bioinformatics*. 2007;23(10):1289-91. doi: 10.1093/bioinformatics/btm091. PubMed
289 PMID: 17379693.
- 290 14. Untergasser A, Cutcutache I, Koressaar T, Ye J, Faircloth BC, Remm M, et al. Primer3--new
291 capabilities and interfaces. *Nucleic Acids Res*. 2012;40(15):e115. doi: 10.1093/nar/gks596.
292 PubMed PMID: 22730293; PubMed Central PMCID: PMCPMC3424584.
- 293 15. Urist MR. Bone: Formation by autoinduction. *Science*. 1965;150(3698):893-9.
- 294 16. Daniel G. Schultz M. FDA Public Health Notification: Life- threatening Complications
295 Associated with Recombinant Human Bone Morphogenetic Protein in Cervical Spine Fusion. 2008.

- 296 17. Carragee EJ, Hurwitz EL, Weiner BK. A critical review of recombinant human bone
297 morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned.
298 Spine J. 2011;11(6):471-91. doi: 10.1016/j.spinee.2011.04.023. PubMed PMID: 21729796.
- 299 18. Jacob M, Chang L, Pure E. Fibroblast activation protein in remodeling tissues. Curr Mol
300 Med. 2012;12(10):1220-43. Epub 2012/07/28. PubMed PMID: 22834826.
- 301 19. Lindvall O, Kokaia Z, Martinez-Serrano A. Stem cell therapy for human neurodegenerative
302 disorders-how to make it work. Nat Med. 2004;10 Suppl:S42-50. doi: 10.1038/nm1064. PubMed
303 PMID: 15272269.

304

Figure Legends

Figure 1: NEDAPS cells isolated from human peripheral nerve tissue and placed in cell culture dish with complete stem cell restrict medium for 24 hours (A), and 7 days (B).

Figure 2: Immunofluorescent staining was performed to identify the pluripotent stem cell


bioRxiv preprint first posted online Apr. 3, 2019; doi: <http://dx.doi.org/10.1101/598433>. The copyright holder for this preprint (which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

markers, and visualized under a confocal microscope. Cells were double stained with a pair of primary antibodies raised in different species, and probed with Alexa Fluor®488 secondary Ab (green) and Alexa 594 2nd Ab (red): (A and B) Sox-2 and Klf-4; (C and D) Oct-4 and c-myc; (E and F) Sox-2 and c-myc; (G and F) Klf-4 and Oct-4.

Figure 3: Electrophoresis of PCR product after the real-time PCR with specific primers for the 4 transcription factors, on the BMP-2 treated cells isolated from human peripheral nerves. The first lane shows a 100pb DNA ladder.

Figure 4: Human NEDAPS cells were morphologically changed to spindle-shaped fibroblastic cells (A), and stained strongly positive for fibroblast activation protein alpha positive (B).

Figure 1



bioRxiv preprint first posted online Apr. 3, 2019; doi: <https://doi.org/10.1101/598433>. The copyright holder for this preprint (which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).






Figure 2




bioRxiv preprint doi: <https://doi.org/10.1101/598433>; this version posted October 1, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

Figure 3



bioRxiv preprint first posted online Apr. 3, 2019; doi: <http://dx.doi.org/10.1101/598433>. The copyright holder for this preprint (which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Figure 4



bioRxiv preprint doi: <https://doi.org/10.1101/598433>; this version posted April 3, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

KLF4

c-Myc

OCT4

SOX2



Figure

Table I - Primers Utilized for RT-PCR Amplification of human specimens

Target	Forward Primer	Reverse Primer	Product Size
Sox2	agaacccaagatgcacaac	gggcagcgtgtacttacct	200
c-Myc	acccgctcaacgacagcagc	ccgtggggaggactcggagg	104
KLF4	ctgaacagcagggactgtca	gtgtgggtggctgttcttt	218
Oct4	agcgatcaagcagcgactat	agagtggtagcggagacagg	202

bioRxiv preprint first posted online Apr. 3, 2019; doi: <http://dx.doi.org/10.1101/598433>. The copyright holder for this preprint (which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](#).